ArticleCNS neuroscience & therapeutics2021
Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma.
Article in CNS neuroscience & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 112 citations in OpenAlex.
- PSMB8: an immune-related prognostic marker for low-grade gliomas.Translational cancer research · 2026Article
- Construction of PANoptosis-related lncRNA prognostic model and immunotherapy sensitivity analysis in lung adenocarcinoma.Journal of cardiothoracic surgery · 2026Article
- From Integrated Analysis to Clinical Insight: ncRNA-Mediated Ferroptosis in Glioblastoma.Cancers · 2026Review
- Ferroptosis in Glioblastoma and Neuroblastoma: Molecular Mechanisms and Novel Therapeutic Strategies.Current issues in molecular biology · 2026Review
- 2D nanomaterial-triggered ferroptosis in cancer therapy.Journal of nanobiotechnology · 2025Review
- ZBTB20 promotes ferroptosis through inhibiting TMEM109 expression in glioblastoma cells.International journal of oncology · 2025Article
- Development of a Novel Risk Signature for Predicting the Prognosis and Immunotherapeutic Response of Prostate Cancer by Integrating Ferroptosis and Immune-Related Genes.Molecular biotechnology · 2025Article
- Transcriptomic HEPN1 signatures predict treatment response in low grade glioma.Discover oncology · 2025Article
- Roles and Prospective Applications of Ferroptosis Suppressor Protein 1 (FSP1) in Malignant Tumor Treatment.Current oncology (Toronto, Ont.) · 2025Review
- Analysis of ABCC3 in glioma progression: implications for prognosis, immunotherapy, and drug resistance.Discover oncology · 2025Article
- Integrated multi-optosis model for pan-cancer candidate biomarker and therapy target discovery.Frontiers in bioinformatics · 2025Article
- Integrative analysis of polyamine metabolism-related genes in gliomas: implications for prognosis and therapy.Frontiers in oncology · 2025Article
- Article
- Unveiling the therapeutic prospects of IFNW1 and IFNA21: insights into glioma pathogenesis and clinical significance.Neurogenetics · 2024Article
- Identification of a ferroptosis-related gene signature for the prognosis of pediatric neuroblastoma.Translational cancer research · 2024Article
- Article
- Article
- Machine learning-based investigation of regulated cell death for predicting prognosis and immunotherapy response in glioma patients.Scientific reports · 2024Article
- Modulating ferroptosis sensitivity: environmental and cellular targets within the tumor microenvironment.Journal of experimental & clinical cancer research : CR · 2024Review
- Exploring the relationship between anastasis and mitochondrial ROS-mediated ferroptosis in metastatic chemoresistant cancers: a call for investigation.Frontiers in immunology · 2024Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
aimsGlioma is a highly invasive brain tumor, which makes prognosis challenging and renders patients resistant to various treatments. Induction of cell death is promising in cancer therapy. Ferroptosis, a recently discovered regulated cell death, can be induced for killing glioma cells. However, the prognostic prediction of ferroptosis-related genes (FRGs) in glioma remains elusive.
methodsThe mRNA expression profiles and gene variation and corresponding clinical data of glioma patients and NON-TUMOR control were downloaded from public databases. Risk score based on a FRGs signature was constructed in REMBRANDT cohort and validated in other datasets including CGGA-693, CGGA-325, and TCGA.
resultsOur results demonstrated that the majority of FRGs was differentially expressed among GBM, LGG, and NON-TUMOR groups (96.6%). Furthermore, the glioma patients with low-risk score exhibited a more satisfactory clinical outcome. The better prognosis was also validated in the glioma patients with low-risk score no matter to which grade they were affiliated. Functional analysis revealed that the high-risk score group was positively correlated with the enrichment scores for immune checkpoint blockade-related positive signatures, indicating the critical role of glioma immunotherapy via risk score.
conclusionA novel FRGs-related risk score can predict prognosis and immunotherapy in glioma patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.